Published in Basic Clin Pharmacol Toxicol on July 15, 2009
Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol (2013) 0.90
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet Genomics (2013) 0.80
Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers. Pharmacotherapy (2013) 0.77
Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report. Indian J Med Res (2016) 0.75
Diabetes as a risk factor for medication-related osteonecrosis of the jaw. J Dent Res (2014) 0.75
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother (2008) 2.52
Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther (2002) 1.64
Pharmacokinetics of oral vitamin D(3) and calcifediol. Bone (2014) 1.58
Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol (2004) 1.58
Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother (2005) 1.42
Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos (2002) 1.40
Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med (2007) 1.39
Pharmacogenetics of drug-induced liver injury. Hepatology (2010) 1.38
Pharmacogenetics-based therapeutic recommendations--ready for clinical practice? Nat Rev Drug Discov (2005) 1.35
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother (2011) 1.26
Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol (2008) 1.26
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics (2009) 1.25
The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch Gen Psychiatry (2011) 1.16
Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol (2005) 1.10
Characterization of a functional promoter polymorphism of the human tryptophan hydroxylase 2 gene in serotonergic raphe neurons. Biol Psychiatry (2007) 1.09
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet (2011) 1.08
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther (2006) 1.07
Oral supplementation with 25(OH)D3 versus vitamin D3: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity. J Bone Miner Res (2012) 1.05
Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet (2008) 1.05
Study on the dosing accuracy of commonly used disposable insulin pens. Diabetes Technol Ther (2012) 1.04
AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther Drug Monit (2006) 1.04
Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenet Genomics (2008) 1.02
CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics (2010) 1.02
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. Clin Pharmacokinet (2011) 1.00
Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. Eur J Endocrinol (2010) 0.99
Baseline brain perfusion and the serotonin transporter promoter polymorphism. Biol Psychiatry (2009) 0.98
Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta (2009) 0.97
Novel mutations of the extraneuronal monoamine transporter gene in children and adolescents with obsessive-compulsive disorder. Int J Neuropsychopharmacol (2007) 0.96
Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther (2004) 0.95
Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism. Biol Psychiatry (2007) 0.94
Pattern profiling of the herbal preparation picroliv using liquid chromatography-tandem mass spectrometry. J Chromatogr A (2004) 0.93
Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. Cancer Chemother Pharmacol (2013) 0.93
Absorption, pharmacokinetics, and safety of triclosan after dermal administration. Antimicrob Agents Chemother (2009) 0.92
An amperometric biosensor with human CYP3A4 as a novel drug screening tool. Biochem Pharmacol (2003) 0.92
The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther (2002) 0.92
Influence of posture on pharmacokinetics. Eur J Clin Pharmacol (2008) 0.91
Association of CYP2D6 genotypes and personality traits in healthy individuals. J Clin Psychopharmacol (2006) 0.90
Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet (2005) 0.90
How may anticancer chemotherapy with fluorouracil be individualised? Clin Pharmacokinet (2006) 0.89
Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways. Pharmacogenomics (2010) 0.88
Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration. Antimicrob Agents Chemother (2009) 0.88
Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites. Hum Mol Genet (2011) 0.87
Pharmacogenetics-guided dose modifications of antidepressants. Clin Lab Med (2008) 0.87
Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers. Eur J Clin Pharmacol (2006) 0.87
Sex-specific differences in side effects of psychotropic drugs: genes or gender? Pharmacogenomics (2009) 0.87
Dried blood spots: concepts, present status, and future perspectives in bioanalysis. Drug Test Anal (2014) 0.85
Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol (2002) 0.85
Discovery of a new class of natural product-inspired quinazolinone hybrid as potent antileishmanial agents. J Med Chem (2013) 0.85
Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography-mass spectrometry after solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.85
Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. Child Adolesc Psychiatry Ment Health (2009) 0.85
In vivo role of cytochrome P450 2E1 and glutathione-S-transferase activity for acrylamide toxicokinetics in humans. Cancer Epidemiol Biomarkers Prev (2009) 0.85
Implications of pharmacogenetics for individualizing drug treatment and for study design. J Mol Med (Berl) (2003) 0.84
Torsades de pointes tachycardia induced by common cold compound medication containing chlorpheniramine. Eur J Clin Pharmacol (2010) 0.84
A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole. Clin Pharmacokinet (2013) 0.84
Effect of concurrently coadministered drugs on the pharmacokinetic/pharmacodynamic profile of centchroman, a nonsteroidal oral contraceptive, in rats. Contraception (2006) 0.84
Atypical antipsychotics in severe anorexia nervosa in children and adolescents--review and case reports. Eur Eat Disord Rev (2008) 0.83
In Vitro and In Vivo pharmacokinetic studies of bulaquine (analogue of primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey--highlighting species similarities and differences. Biopharm Drug Dispos (2007) 0.83
Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst (2002) 0.82
The effect of silymarin on oral nifedipine pharmacokinetics. Planta Med (2007) 0.82
Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarker. J Pharm Biomed Anal (2012) 0.82
Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients? Antivir Ther (2010) 0.82
Pharmacogenetics-based new therapeutic concepts. Drug Metab Rev (2004) 0.81
Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy. Cancer Chemother Pharmacol (2014) 0.81
Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet (2009) 0.81
Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metab Dispos (2011) 0.81
Metabolism of CDRI-85/92, a new potent anti-ulcer agent, involving cis-trans conversion. Drug Metabol Drug Interact (2004) 0.81
Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers. Eur J Clin Pharmacol (2009) 0.81
Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual. Eur J Clin Pharmacol (2008) 0.81
CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin Pharmacol Ther (2004) 0.81
Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers. Drug Metab Dispos (2013) 0.81
Clinical impact of fluvoxamine-mediated long QTU syndrome. Eur J Clin Pharmacol (2011) 0.81
Rapid and simple method for the analysis of nateglinide in human plasma using HPLC analysis with UV detection. J Pharm Biomed Anal (2003) 0.81
Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort. Pharmacogenomics (2010) 0.81
Profiling of mercapturic acids of acrolein and acrylamide in human urine after consumption of potato crisps. Mol Nutr Food Res (2012) 0.81
Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis - an open pilot study. J Crohns Colitis (2012) 0.81
Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam. J Clin Pharmacol (2014) 0.80
Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib. J Thorac Oncol (2015) 0.80
Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected? Eur J Clin Pharmacol (2008) 0.80
Modeling NSCLC progression: recent advances and opportunities available. AAPS J (2013) 0.80
Natriuretic peptides in therapy for decompensated heart failure. Eur J Clin Pharmacol (2011) 0.80
Serotonin syndrome with tramadol and citalopram. Am J Psychiatry (2004) 0.80
CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies. Pharmacogenomics (2009) 0.80
Synthesis and bioevaluation of novel 4-aminoquinoline-tetrazole derivatives as potent antimalarial agents. Eur J Med Chem (2013) 0.80
Optimized intrapleural cisplatin chemotherapy with a fibrin carrier after extrapleural pneumonectomy: a preclinical study. J Thorac Cardiovasc Surg (2011) 0.79
A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. Pharmacogenomics (2010) 0.79